OptimizeRx Co. (NASDAQ:OPRX) Receives $11.58 Consensus Price Target from Analysts

Shares of OptimizeRx Co. (NASDAQ:OPRX) have earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $10.42.

OPRX has been the subject of several research reports. Barclays cut their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday. Roth Mkm reiterated a “buy” rating and issued a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research report on Thursday. William Blair restated an “outperform” rating on shares of OptimizeRx in a research report on Thursday. JMP Securities dropped their price target on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research report on Thursday. Finally, Royal Bank of Canada decreased their price objective on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OPRX. Mirae Asset Global Investments Co. Ltd. purchased a new position in OptimizeRx in the 1st quarter valued at about $542,000. BNP Paribas Financial Markets grew its stake in OptimizeRx by 283.6% during the 1st quarter. BNP Paribas Financial Markets now owns 27,910 shares of the company’s stock valued at $339,000 after purchasing an additional 20,634 shares in the last quarter. Blair William & Co. IL increased its holdings in OptimizeRx by 5.6% during the 1st quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock worth $9,508,000 after purchasing an additional 41,469 shares during the last quarter. Vanguard Group Inc. raised its position in shares of OptimizeRx by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock valued at $12,482,000 after purchasing an additional 6,291 shares in the last quarter. Finally, First Light Asset Management LLC boosted its stake in shares of OptimizeRx by 0.6% during the 1st quarter. First Light Asset Management LLC now owns 1,737,584 shares of the company’s stock valued at $21,112,000 after buying an additional 10,286 shares during the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Stock Performance

NASDAQ OPRX opened at $3.83 on Thursday. The business has a 50 day moving average price of $6.60 and a 200 day moving average price of $8.98. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.07 and a quick ratio of 3.07. The company has a market capitalization of $70.07 million, a P/E ratio of -2.88 and a beta of 1.32. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $16.65.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.